- BNF:
- 4.4
- Status:
- Amber
- Decision Date:
- None
Comments
See shared care guidelines for drugs used in the management of ADHD
First line drug choice
MHRA drug safety update - methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations. (Sep 2022)
Amber Drug Classifications
- 1: Requiring specialist assessment to enable patient selection and initiation of treatment
- 3: Requiring short or medium term specialist monitoring of toxicity
search again
